An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study Prostate Cancer and Prostatic Diseases advance online publication, September 2 2014. doi:10.1038/pcan.2014.24 Authors: L Klotz, D Drachenberg, R Singal, A Aprikian, Y Fradet, M Kebabdjian, M Zarenda & J Chin
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research